Anagram Therapeutics develops orally delivered enzyme therapies for malabsorption syndromes and nutrient deficiencies.
Anagram Therapeutics has raised $250.0M in total funding. The most recent round was Private Equity. The last funding was announced in May 2026.
Anagram Therapeutics's investors include Blackstone Life Sciences, Cystic Fibrosis Foundation, Miller Family Trust.
Anagram Therapeutics is headquartered in Boston, United States.
Anagram Therapeutics develops orally delivered enzyme therapies for malabsorption syndromes and nutrient deficiencies.
Anagram Therapeutics is at the Private Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anagram Therapeutics — Funding & Investors." VCBacked, May 7, 2026, https://www.vcbacked.co/company/anagram-therapeutics. Accessed September 15, 2026.
VCBacked. (2026). Anagram Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/anagram-therapeutics
{{cite web |title=Anagram Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/anagram-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated